Similarly, the combination of IgG 2A11 with gemcitabine resulted in lower levels of HMGB1 in tumors than the combination of the control IgGs with gemcitabine, suggesting that RAGE inhibition might modulate HMGB1 levels, either by reducing the expression of HMGB1 in tumor tissues or by increasing the secretion of HMGB1 extracellularly. This evidence concerns the gene AGER and neoplasm.